Spinal Muscular Atrophy Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032) - DelveInsight | Scholar Rock, Biogen, Astellas, AndroScience, Aurimed Pharma, Exicure, Amylon, Amniotics, Roche, NMD Pharma, CANbridge, Alcyone

As per DelveInsight, the Spinal Muscular Atrophy Market is anticipated to evolve immensely in the coming years owing to the expected launch of emerging therapies and the rise in the number of case of Spinal Muscular Atrophy.

DelveInsight's "Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Spinal Muscular Atrophy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Spinal Muscular Atrophy therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Spinal Muscular Atrophy treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Spinal Muscular Atrophy: An Overview
Spinal muscular atrophy (SMA) is an autosomal recessive rare neuromuscular disorder that is characterized by progressive muscle wasting because of the loss of motor neurons in the spinal cord (anterior horn), which controls voluntary muscle movement. SMA is one of the most common causes of infant death and mobility impairment. It mostly affects proximal muscles and respiratory muscles. The most common form of SMA is known as '5q SMA' due to its genetic cause.

SMA follows the autosomal mode of inheritance, and its onset ranges from infants to adolescence. Human chromosome 5q has two identical genes, SMN1 and SMN2. SMN1 encodes 100% fully functional SMN protein, whereas SMN2 encodes only 10-20% of functional SMN protein. Mutation of SMN1 is the main reason for this disorder, and the severity of the disease depends on the number of SMN2 gene copies. The healthy person carries 2 copies of the SMN2 gene, but in SMA-affected patients, it can vary from 1 to 4. The greater the number of SMN2 gene copies, the milder the effect of the disorder. The other SMAs form a genetically very heterogeneous group of rare disorders, differing in their mode of inheritance, the topography of the muscular deficit, and the association with other neurological abnormalities.

Spinal Muscular Atrophy Market Key Facts
• According to the National Organization for Rare Disorders (NORD), the prevalence of all types of SMA has been estimated to be 4-7.8 per 100,000 live births. Approximately 80% of SMA patients have the Werdnig-Hoffmann form, i.e. Type 1 SMA. It further stated that the condition is diagnosed in only 150 to 200 people. Moreover, 1 in 50 people (approximately 6 million Americans) are carriers.
• National Institute for Health and Care Excellence (NICE) (2018) reported that SMA affects an estimated 1 in 6,000 to 1 in 10,000 births worldwide. It is estimated that about 100 people are born with SMA per year in the UK, and there are currently between 1,200 and 2,500 children and adults in the UK living with SMA.
• A study conducted by Ghetti et al. (2020) stated that currently, the estimated number of SMA patients in Italy is 850, corresponding to a prevalence of 1.41 per 100,000 inhabitants. This number, confirmed by patient associations, are likely underestimated due to the lack of follow-up of patients with less severe forms.
• As per Delveinsight's analysis, the total prevalent population of SMA in the 7MM was around 20,000 cases in 2020, out of which the United States accounted for nearly 13,000 cases in 2020.

Discover How Spinal Muscular Atrophy Market Will Grow by 2032:
https://www.delveinsight.com/report-store/spinal-muscular-atrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Spinal Muscular Atrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Spinal Muscular Atrophy therapies in the market. It also provides a detailed assessment of the Spinal Muscular Atrophy market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Spinal Muscular Atrophy drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Spinal Muscular Atrophy Epidemiology
The epidemiology section covers detailed insights into the historical, and current Spinal Muscular Atrophy patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Spinal Muscular Atrophy Epidemiology Segmented as -
• Total Prevalent Population of Spinal Muscular Atrophy (SMA) in the 7MM [2019-2032]
• Age-specific Prevalence of Spinal Muscular Atrophy (SMA) in the 7MM [2019-2032]
• Type-specific Prevalence of Spinal Muscular Atrophy (SMA) in the 7MM [2019-2032]

Get Key Insights Into the Evolving Spinal Muscular Atrophy Epidemiology Trends @
https://www.delveinsight.com/report-store/spinal-muscular-atrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Spinal Muscular Atrophy Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Muscular Atrophy market or expected to be launched during the study period. The analysis covers the market share by Spinal Muscular Atrophy drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Spinal Muscular Atrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Spinal Muscular Atrophy Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Spinal muscular atrophy. Currently, Scholar Rock is leading the therapeutics market with its Spinal muscular atrophy drug candidates in the most advanced stage of clinical development.

Leading Companies in the Spinal Muscular Atrophy Therapeutics Market Include
• Scholar Rock
• Biogen
• Astellas Pharma
• Alcyone Therapeutics
• AndroScience Corporation
• Hanugen Therapeutics
• Voyager Therapeutics
• Hoffmann-La Roche
• Catalyst Pharmaceuticals
• NMD Pharma
• Biohaven Pharmaceuticals
• CANbridge Pharmaceuticals Inc.
• Aurimed Pharma
• Exicure
• Amylon Therapeutics
• Amniotics
And Many More

Emerging and Marketed Spinal Muscular Atrophy Therapies Covered in the Report Include
• Apitegromab: Scholar Rock
• ACTX-401: Alcyone Therapeutics
And Many Others

Learn More About the Emerging Therapies & Key Companies in the Spinal Muscular Atrophy Therapeutics Market:
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Spinal Muscular Atrophy Competitive Intelligence Analysis
4. Spinal Muscular Atrophy Market Overview at a Glance
5. Spinal Muscular Atrophy Background and Overview
6. Spinal Muscular Atrophy Patient Journey
7. Spinal Muscular Atrophy Epidemiology and Patient Population
8. Spinal Muscular Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Spinal Muscular Atrophy Unmet Needs
10. Key Endpoints of Spinal Muscular Atrophy Treatment
11. Spinal Muscular Atrophy Marketed Products
12. Spinal Muscular Atrophy Emerging Therapies
13. Spinal Muscular Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Spinal Muscular Atrophy Market Outlook (7 major markets)
16. Spinal Muscular Atrophy Access and Reimbursement Overview
17. KOL Views on the Spinal Muscular Atrophy Market.
18. Spinal Muscular Atrophy Market Drivers
19. Spinal Muscular Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market

Lower-Limb Spasticity Market
https://www.delveinsight.com/report-store/lower-limb-spasticity-market

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market

Cancer Cachexia (CC) Market
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights

Hepatitis C Market
https://www.delveinsight.com/report-store/hepatitis-c-market

Open-Angle Glaucoma Market
https://www.delveinsight.com/report-store/open-angle-glaucoma-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Papilloma Market
https://www.delveinsight.com/report-store/papilloma-market

Peripheral Neuritis Market
https://www.delveinsight.com/report-store/peripheral-neuritis-market

Renal Insufficiency Market
https://www.delveinsight.com/report-store/renal-insufficiency-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market

Relapsing Multiple Sclerosis (RMS) Market
https://www.delveinsight.com/report-store/relapsing-multiple-sclerosis-rms-market

Asthma Market
https://www.delveinsight.com/report-store/asthma-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Corneal Dystrophy Market
https://www.delveinsight.com/report-store/corneal-dystrophy-market

Peripheral Vascular Devices Global Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market

Physiotherapy Equipment Market Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Herpes Simplex Market
https://www.delveinsight.com/report-store/herpes-simplex-market

Hairy Cell Leukemia (HCL) Market
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.